title: Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
authors.affiliation: Center for Molecular Medicine Cologne-CMMC, University of Cologne, and Department I Internal Medicine, University Hospital Cologne, Uniklinik Köln, Robert-Koch-Straße 21, D-50931 Köln, Cologne, Germany.
authors.forename: Andreas A
authors.initials: AA
authors.lastname: Hombach
authors.forename: Hinrich
authors.initials: H
authors.lastname: Abken
mesh_terms: D000818:Animals; D000943:Antigens, Differentiation / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods* / Q000639:trends; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D020239:Receptor Cross-Talk; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000235:genetics / Q000276:immunology*
chemical_list: D000943:Antigens, Differentiation; C406562:OX40Ig; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9